A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms TOMORROW
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has been completed in Hungary according to European Clinical Trials Database.
    • 22 Nov 2016 This trial has been completed in Hungary (end date: 26 Sep 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top